Get the Stockscreener App
24.98
0.22%
-15.84
After Hours:
24.99
0.005
+0.02%
Flexion Therapeutics, Inc. stock is traded at $24.98, with a volume of 0.
It is down -0.22% in the last 24 hours and down -2.04% over the past month.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
See More
Previous Close:
$9.14
Open:
$24.985
24h Volume:
0
Relative Volume:
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-13.29
EPS:
-1.88
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
-2.04%
6M Performance:
+10.95%
1Y Performance:
-15.87%
1-Day Range:
$24.98
$24.98
1-Week Range:
$24.98
$24.98
52-Week Range:
$24.98
$24.98
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Name
Flexion Therapeutics, Inc.
Sector
Phone
781-305-7777
Address
10 Mall Road, Suite 301, Burlington
Compare FLXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
24.98 | 0 | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
151.54 | 70.46B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 47.78B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.69 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.01 | 19.16B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.16 | 13.56B | 2.99B | 1.21B | 1.13B | 25.06 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Aug-20-20 | Initiated | Goldman | Neutral |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jul-29-20 | Initiated | Credit Suisse | Outperform |
| Jun-25-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Dec-27-19 | Reiterated | The Benchmark Company | Buy |
| Dec-05-19 | Initiated | Craig Hallum | Buy |
| Nov-25-19 | Initiated | BTIG Research | Buy |
| May-09-19 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-04-19 | Reiterated | Needham | Buy |
| Jan-04-19 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-28-18 | Initiated | The Benchmark Company | Buy |
| Oct-09-17 | Reiterated | Needham | Buy |
| Aug-24-17 | Initiated | Northland Capital | Outperform |
| Dec-22-16 | Initiated | Raymond James | Strong Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| Jul-21-16 | Initiated | Lake Street | Buy |
| May-03-16 | Resumed | Wells Fargo | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Sep-09-15 | Reiterated | Needham | Buy |
View All
Flexion Therapeutics, Inc. Stock (FLXN) Latest News
Value vs Growth Ratio Hits Cycle Low—Top Value Picks to Buy - The Globe and Mail
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program - The Manila Times
Musculoskeletal Pain Therapeutics Market Size in 7MM - openPR.com
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Catalyst Pharmaceuticals Appoints William T. Andrews, MD, FACP as Chief Medical Officer - citybiz
Catalyst Pharmaceuticals Taps Harvard-Yale Veteran with 18 Years Rare Disease Expertise as New CMO - Stock Titan
Osteoarthritis Therapeutics Market Emerging Tech Trends to Watch from 2025 to 2032 - newstrail.com
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies - The Manila Times
Marquis Who's Who Honors Shomari Hogan, MD, for Expertise in Consulting Services - 24-7 Press Release Newswire
Knee osteoarthritis Market: Epidemiology, Therapies, - openPR.com
Musculoskeletal Pain Treatment Market Size in 7MM is expected - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Osteoarthritis Therapeutics Market Size Unlocking New Opportunities for Success As Revealed In New Report - WhaTech
Anti-Inflammatory Therapeutics Market Recent - openPR.com
Dollar Gains on US Economic News and Hawkish Bostic - The Globe and Mail
Musculoskeletal Pain Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, - openPR.com
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight - Barchart.com
USDCAD Completes A Correction Within An Uptrend - The Globe and Mail
Neogen (NEOG) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Nio Stock: The EV Darling That Still Can’t Deliver Profits - The Globe and Mail
Cautious Optimism for Building Products Distribution Rising as Sustained Demand for New Residential Construction Expected - The Globe and Mail
Knee Osteoarthritis Pipeline: Over 50 Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com
Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301 - marketscreener.com
Flexion Therapeutics, Inc. Announces Executive Changes - MarketScreener
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - The Globe and Mail
I'm Buying This Nvidia-Backed AI Company Before It Explodes - The Globe and Mail
Osteoarthritis Treatment Market Trends and Forecast 2034 - openPR.com
Rivian's Autonomy Push Is Another Potential Failure - The Globe and Mail
Flexion Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Flexion Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Rocket Lab (RKLB) Q4 Earnings: What To Expect - The Globe and Mail
Q4 Earnings Roundup: Baxter (NYSE:BAX) And The Rest Of The Medical Devices & SuppliesDiversified Segment - The Globe and Mail
Armlogi Advances Supply Chain Solutions with Roadie, a UPS Company, Expanding Last-Mile Delivery Coverage to 97% of U.S. - The Globe and Mail
AMD Is Looking Like a No-Brainer Buy, Here's Why. - The Globe and Mail
Joint Pain Injections Market Set to Surge to $13.18 Billion by 2031 at a 7.7% CAGR - EIN News
3 Steel Stocks to Gain Strength as Tariffs Reshape the Market - The Globe and Mail
Week Ahead In Pharma (May 10- 14): FDA Decision, Data Readouts (RCKT, AVRO, FLXN, RARE, HRTX…) - RTTNews
CPRXCatalyst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Musculoskeletal Pain Therapeutics Market Size in the 7MM is expected to grow by 2034 and estimates DelveInsight - Barchart
Joint Pain Injections Market: Unleashing Growth Opportunities - openPR
[Expert View] Osteoarthritis Treatment Market Innovating Therapies for Joint Health Improvement | 20242033 - openPR
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
iBio Strengthens Board with Appointment of Two New Independent Directors - GlobeNewswire
PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration - Nature
Osteoarthritis Therapeutics Market Size, Report By 2034 - Precedence Research
Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Flexion Therapeutics, Inc. Stock (FLXN) Financials Data
There is no financial data for Flexion Therapeutics, Inc. (FLXN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
8.43%
1.68%
Cap:
|
Volume (24h):